Media Discussion: ”Your Body, Your Life, Your Decision” - Facts and Myths regarding Oral Contraceptive
- Facts and Myths regarding oral contraceptive
- When taken consistently and correctly, Combined Hormonal Contraceptives are one of the most reliable methods of preventing pregnancy; they have a failure rate of ≤ 1 (less than 1 in 100 women)1
Jakarta, 24 May 2016
PT Bayer Indonesia held a media discussion, "Your Body, Your Life, Your Decision" - Facts and myths regarding oral contraceptive. This media discussion is revealed the facts and information related to scientific research to answer the myths that lead to women in Asia are afraid to use oral contraceptive.
Currently, nine out of 10 women in the world using the modern contraception2.The modern contraceptive methods of contraception are sterilization, contraception intrauterine such as copper, condoms and other hormonal contraceptives such as the pill. The modern contraceptive methods are reliable to prevent pregnancy than traditional contraceptives3. Pill ranks third as the most common method of contraception in the world today, which has the widest geographical distribution than other contraceptives. In Asia, 6.4% women using the pill contraception and in Indonesia by 13.6%, while the highest use of the pill to the Southeast Asian region is occupied by Thailand at 35% 4.
The main factor of the low use of oral contraceptive for contraception is the myth regarding the oral contraceptive. According to dr. Boy Abidin, SpOG, many women are afraid to use oral contraceptive caused the fear of infertile, fat, and cancer. Though this is not true. According to scientific research, using oral hormonal contraceptives do not cause negative effects on the level of fertility5,6. Also it is not true that oral contraceptives cause weight gain. Scientific research shows that weight gain is not caused by the use of oral contraceptive, but because of the age, diet and physical activity7". Dr. Boy Abidin, SpOG added that the use of oral contraceptive can reduce the risk of ovarian and endometrial cancer. Data show that the risk of cancer decreases in women taking oral contraceptives for long term8. The study also showed that the decrease in the risk of endometrial cancer by 50% in women who use the oral contraceptive9-15.
Most of oral contraceptive today are combined oral contraceptives ("COCs" or “combined pills”) containing two types of hormone: estrogen and progestogen. The vast majority of combined pills contain different doses of the estrogen ethinyl estradiol. There are a number of variations and doses relating to the progestogen. The progestogen component is primarily responsible for the contraceptive effect. The oral contraceptives are available with various types of progestin. The specific progestin could offer non contraceptive effects, such as the fight against the effects of estrogen which causes water retention (weight gain) and associated symptoms. Other non-contraceptive effects including treatment of emotional and physical symptoms of premenstrual dysphoric disorder (PMDD), the most severe form of premenstrual syndrome (PMS)16. "The pill contraceptive is very reliable to avoid pregnancy when taken consistently and correctly, COCs are one of the most reliable methods of preventing pregnancy; they have a failure rate of ≤ 1 (less than 1 in 100 women)1
Many women think that taking an oral contraceptive is a hassle because they often forgotten. Actually, it is simple. If you forget within 12 hours, take it as soon as you remember, Take your next dose at the regular time. This means you may take 2 doses on the same day17, said dr. Boy Abidin, SpOG.
Every woman has the right to obtain proper information and consultation associated with contraceptive methods. By providing them with evidence based information and knowledge of oral contraceptive will help women understand risk and benefit to dispel myths.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com or www.bayer.co.id.
Head of Communications
PT Bayer Indonesia
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
- James Trussel, PhD, Contraceptive Failure in the United States, National Institute of Health 2011; 83 (5):397-404
- World Contraception Day website, http://www.your-life.com
- United Nations (2013), World Contraceptive Patterns
- Mansour D,et al.Contraception.2011 Nov;84(5):465-77.
- Cronin M, et al. Obstet Gynecol. 2009 Sep;114(3):616-22.
- Redmond G, et al. Contraception 60:81, 1999. Carpenter S, Neinstein LS. J Adolesc Health Care 7:342, 1986. Reubinoff BE, et al. Fertil Steril 64:963, 1995. Moore LL, et al. Contraception 52:215, 1995. Gupta S, Hum Reprod Update 6:427, 2000. Coney P, et al. Contraception 63:297, 2001.
- Havrilesky et al. Evidence report/technology assessment 2013:1-514
- Vessey et al. Contraception. 2013;88(6):678-683;
- Hannaford et al. BMJ 2007;335:651;
- Havrilesky et al. Evidence report/technology assessment 2013:1-514;
- Jick et al. Obstet Gynecol1993;82:931-5;
- Hulka et al. JAMA 1982;247:475-7;
- Kaufman et al N Engl J Med 1980;303:1045-7;
- NICHD. JAMA 1987;257:796-800.
- James Trussel, PhD, Contraceptive Failure in the United States, National Institute of Health 2011; 83 (5): 397-404
- Drospirenon – patient package insert